Prognostic Factors in Papillary Thyroid Cancer: An Evaluation of 601 Consecutive Patients

Tumor Biology ◽  
2005 ◽  
Vol 26 (2) ◽  
pp. 57-64 ◽  
Author(s):  
Päivi Siironen ◽  
Johanna Louhimo ◽  
Stig Nordling ◽  
Ari Ristimäki ◽  
Hanna Mäenpää ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid

scholarly journals The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132821 ◽  
Author(s):  
Agnieszka Czarniecka ◽  
Monika Kowal ◽  
Dagmara Rusinek ◽  
Jolanta Krajewska ◽  
Michal Jarzab ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Mutation Status ◽  
Risk Of Relapse

scholarly journals Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers

2020 ◽  
Vol 10 (2) ◽  
pp. 52
Author(s):  
Andra Piciu ◽  
Maria-Iulia Larg ◽  
Doina Piciu
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Genetic Mutation ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Early Assessment ◽  
Pet Ct ◽  
Ct Evaluation

In thyroid neoplastic pathology, the BRAF V600E mutation is shown to be involved in the oncogenesis of papillary thyroid cancer and its subtypes. The purpose of this study is to evaluate the correlation between the mutation of the BRAF V600E oncogene and the pathological standardized uptake values (SUV) at the F18-fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) evaluation, for a group of 20 patients with radically treated (total thyroidectomy and radioiodine therapy) papillary thyroid cancer, with subclinical persistent disease, at 6 months after the initial treatment. We analyzed the correlations between the values of SUV and the presence of the BRAF mutation as well with other prognostic factors such as stage, age, specific tumor markers (thyroglobulin and anti-thyroglobulin), extrathyroid extension, the presence of metastatic lymph nodes or distant metastasis. The value of SUV in the case of BRAF+ (positive) patients was higher than in the negative ones, but without statistical significance, thus, the values of the SUV cannot be a predictable factor for the presence of the genetic mutation. There was a statistically significant correlation in BRAF+ subgroup between the SUV values and the positive resection limit following surgery, showing a higher SUV value in the PET/CT evaluation. No correlation was observed between the aforementioned prognostic factors involved in papillary thyroid cancer and the BRAF V600E mutation.

Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I

Endocrine ◽  
2018 ◽  
Vol 62 (1) ◽  
pp. 149-158 ◽  
Author(s):  
Xin-Yun Zhang ◽  
Hong-Jun Song ◽  
Zhong-Ling Qiu ◽  
Chen-Tian Shen ◽  
Xiao-Yue Chen ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Children And Adolescents ◽  
Papillary Thyroid Cancer ◽  
Pulmonary Metastases ◽  
Papillary Thyroid

scholarly journals The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer

Cancer ◽  
2011 ◽  
Vol 118 (7) ◽  
pp. 1764-1773 ◽  
Author(s):  
Tae Hyuk Kim ◽  
Young Joo Park ◽  
Jung Ah Lim ◽  
Hwa Young Ahn ◽  
Eun Kyung Lee ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Clinical Outcome ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Poor Clinical Outcome

scholarly journals Secular trends in the prognostic factors for papillary thyroid cancer

2014 ◽  
Vol 171 (5) ◽  
pp. 667-675 ◽  
Author(s):  
Hoonsung Choi ◽  
Jung Ah Lim ◽  
Hwa Young Ahn ◽  
Sun Wook Cho ◽  
Kyu Eun Lee ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Papillary Thyroid Cancer ◽  
Tumor Size ◽  
Secular Trends ◽  
Papillary Thyroid ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Male Sex ◽  
Over Time

ObjectiveWith the recent increasing rates of screening for thyroid cancer, the cancers now tend to be smaller and less aggressive than those that are diagnosed when presented with symptoms, suggesting changes in the clinical validity of conventional prognostic factors for outcomes. We performed the retrospective study to identify the secular trends in the prognostic factors of thyroid cancer.MethodsWe used medical records of 3147 patients diagnosed with papillary thyroid cancer (PTC) at the Seoul National University Hospital Thyroid Cancer Clinic between 1962 and 2009.ResultsDuring the median 5.1-year follow-up, the overall recurrence rate was 13.3%, and male sex, tumor size, lymph node (LN) involvement, and extrathyroidal extension (ETE) were the significant prognostic factors for recurrence. Thyroid cancer-specific mortality was 1.4%, and the associated prognostic factors were older age, male sex, and LN involvement. For tumor recurrence, the hazard ratio (HR) for male sex decreased from 2.809 (95% CI, 1.497–5.269) in the pre-1989 period to 1.142 (95% CI, 0.736–1.772) in the post-1999 period. The pathologic characteristics, such as tumor size, LN involvement, and ETE, showed similar or increasing HRs over the time periods. For cancer-specific mortality, the HR for male sex decreased from 6.460 (95% CI, 1.714–24.348) in the pre-1990 period to 0.781 (95% CI, 0.083–7.379) in the post-1999 period.ConclusionThe risk for poor outcomes in PTC associated with male sex decreased over time; in contrast, the risk associated with pathologic characteristics remained the same or increased over time. These trends might be associated with recent changes in the characteristics of patients with thyroid cancer.

Sign in / Sign up

Export Citation Format

Share Document